Bristol Myers Squibb has successfully completed the acquisition of RayzeBio, Inc., a biopharmaceutical company known for its pioneering work in the development of radiopharmaceutical therapeutics (RPTs) for the treatment of solid tumors. This acquisition bolsters Bristol Myers Squibb's oncology pipeline, particularly in the area of RPTs, and is expected to unlock new opportunities for growth and innovation in the coming years.